insights_auto
Why is GNLX up 2,40%?
Dive Deeperchevron_right
GNLX:NASDAQ
Genelux Corp
US$2,56
arrow_upward
+2,40%(+0,060) 1D
9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
US$2,48
High
US$2,57
Low
US$2,47
Mkt. cap
115,83 ລ້ານ
Avg. vol.
275,44 ພັນ
Volume
154,65 ພັນ
52-wk high
US$8,54
52-wk low
US$2,29
EPS
US$-0,87
Beta
0,59
Shares outstanding
45,24 ລ້ານ
No. of employees
26
Open
US$2,48
High
US$2,57
Low
US$2,47
Mkt. cap
115,83 ລ້ານ
Avg. vol.
275,44 ພັນ
Volume
154,65 ພັນ
52-wk high
US$8,54
52-wk low
US$2,29
EPS
US$-0,87
Beta
0,59
Shares outstanding
45,24 ລ້ານ
No. of employees
26
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 ອາທິດກ່ອນ
Genelux Corporation (GNLX) Slips 0.40% to $2.52 as Shares Hold Above Near-Term Support - Momentum Surge Alerts
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websitegenelux.com